MNOV - MediciNova, Inc.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
10.27
+0.45 (+4.58%)
At close: 4:00PM EST

10.27 0.00 (0.00%)
After hours: 4:34PM EST

Stock chart is not supported by your current browser
Previous Close9.82
Open9.87
Bid8.18 x 800
Ask39.80 x 800
Day's Range9.87 - 10.42
52 Week Range6.87 - 14.50
Volume69,698
Avg. Volume84,311
Market Cap430.121M
Beta (3Y Monthly)1.64
PE Ratio (TTM)N/A
EPS (TTM)-0.41
Earnings DateApr 26, 2017 - May 1, 2017
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est20.00
Trade prices are not sourced from all markets
  • Benzinga9 days ago

    The Daily Biotech Pulse: BioMarin Trims Outlook, MediciNova Enrolls First Patient In Brian Cancer Drug Study

    Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peak (Biotech Stocks Hitting 52-week highs on Jan. 8) Innoviva Inc (NASDAQ: INVA ) Organogenesis Holdings Inc ...

  • GlobeNewswire9 days ago

    MediciNova Announces Initiation of Enrollment in a Clinical Trial of MN-166 (ibudilast) in Glioblastoma

    MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that the first glioblastoma patient has enrolled in the clinical trial of MN-166 (ibudilast) in combination with temozolomide (TMZ, Temodar‑®) for the treatment of recurrent glioblastoma (GBM). The principal investigators are Patrick Y. Wen, M.D., Professor of Neurology, Harvard Medical School and Director, Neuro-Oncology Division at the Dana-Farber Cancer Institute (DFCI) in Boston, and Kerrie McDonald, Ph.D., Associate Professor and Head of Biomarkers and Translational Research at the Lowy Cancer Research Centre, University of New South Wales, Australia.

  • GlobeNewswire10 days ago

    MediciNova Receives Notice of Allowance for New Patent Covering MN-001 and MN-002 for the Treatment of Fibrosis in Japan

    MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that it has received a Notice of Allowance from the Japan Patent Office for a pending patent application which covers MN-001 (tipelukast) and MN-002 (a major metabolite of MN-001)  for the treatment of “fibrosis” which includes a broad range of fibrosis / fibrotic disease in different organs due to different causes. Once issued, the patent maturing from this allowed patent application is expected to expire no earlier than June 2035. The allowed claims cover a composition for inhibiting or treating fibrosis using MN-001 or MN-002.

  • Simply Wall St.last month

    Do Insiders Own Lots Of Shares In MediciNova, Inc. (NASDAQ:MNOV)?

    If you want to know who really controls MediciNova, Inc. (NASDAQ:MNOV), then you'll have to look at the makeup of its share registry. Insiders often own a large chunk of Read More...

  • Zacks Small Cap Research3 months ago

    MNOV: MN-166 to be Studied in Degenerative Cervical Myelopathy…

    In August 2018, MediciNova, Inc. (MNOV) announced plans to conduct a Phase 2/3 trial of MN-166 in degenerative cervical myelopathy (DCM) through an agreement with the University of Cambridge and Cambridge University Hospitals NHS Foundation Trust. The Principal Investigator is Dr. Mark Kotter and the trial is being funded by a grant from the National Institute for Health Research (NIHR) in the United Kingdom. MediciNova is not funding the trial but will provide the study drug supply, regulatory support, and safety monitoring support.

  • Benzinga3 months ago

    The Daily Biotech Pulse: MediciNova Gets Orphan-Drug Status, KemPharm To Offer Shares, Emergent Buys Vaccine Maker

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Biotech stocks hitting 52-week highs on Oct. 3) Amarin Corporation plc (NASDAQ: AMRN ) BIOLINERX Ltd/S ...

  • Zacks Small Cap Research4 months ago

    MNOV: Positive FDA Feedback on ALS Phase 3 Plan…

    On September 25, 2018, MediciNova, Inc. (MNOV) announced that the FDA provided positive feedback in regards to the company’s development plan for MN-166 (ibudilast) in amyotrophic lateral sclerosis (ALS). The FDA did not raise any concerns with the safety of MN-166, only a single trial may be necessary if there is a statistically significant result when comparing MN-166 to placebo in a functional outcome (such as ALSFRS-R), and the agency would like to see a broad range of ALS patients with randomization stratified by baseline disease severity.

  • Zacks Small Cap Research6 months ago

    MNOV: Plenty of Cash to Advance Pipeline Forward

    On July 23, 2018, MediciNova, Inc. (MNOV) filed form 10-Q with financial results for the second quarter of 2018. As expected, the company did not report any revenues. The increase in R&D expenses was primarily due to increased clinical trial costs for MN-166.

  • Zacks Small Cap Research6 months ago

    MNOV: Encouraging Data from Subgroup Analysis of ALS Study

    This group was comprised of 31 subjects out of a total of 49 subjects in the full analysis set. A second subgroup comprised of 39 subjects (out of a total of 67 subjects in the full analysis set) who had either bulbar onset or upper limb onset ALS with or without NIV (the “Early ALS + NIV subgroup”). The score is utilized to keep track of the health of all ALS patients, and is a common outcome measure in ALS clinical trials.

  • When Will MediciNova Inc (NASDAQ:MNOV) Become Profitable?
    Simply Wall St.8 months ago

    When Will MediciNova Inc (NASDAQ:MNOV) Become Profitable?

    MediciNova Inc’s (NASDAQ:MNOV): MediciNova, Inc., a biopharmaceutical company, focuses on acquiring and developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in theRead More...

  • Want To Invest In MediciNova Inc (NASDAQ:MNOV)? Here’s How It Performed Lately
    Simply Wall St.8 months ago

    Want To Invest In MediciNova Inc (NASDAQ:MNOV)? Here’s How It Performed Lately

    After reading MediciNova Inc’s (NASDAQ:MNOV) most recent earnings announcement (31 March 2018), I found it useful to look back at how the company has performed in the past and compareRead More...